38 results
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 Nov 23
Regeneron Reports Third Quarter 2023 Financial and Operating Results
7:10am
high-quality, equitable engagement programs for students and science teachers.
The Company announced that Robert E. Landry, Executive Vice President
DEFA14A
REGN
Regeneron Pharmaceuticals, Inc.
17 May 23
Additional proxy soliciting materials
4:04pm
shareholder engagement program; and
Regeneron’s strong commitment to both long-term sustainability and shareholder value creation.
Board Leadership
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
4 May 23
Regeneron Reports First Quarter 2023 Financial and Operating Results
7:11am
) and APPβ (sAPPβ), biomarkers of target engagement, with maximum reduction of 84% and 90%, respectively. These interim results demonstrated
CORRESP
5srvdg10d yaserxhuba
7 Oct 22
Correspondence with SEC
12:00am
DEFA14A
hi8n 8mqsmmw2t
21 Apr 22
Additional proxy soliciting materials
4:21pm
DEFA14A
85bkkc8m6 0dmb8g2qm
23 Apr 21
Additional proxy soliciting materials
4:21pm
8-K
EX-1.1
kr335e0ira9w5xikt rm
12 Aug 20
Entry into a Material Definitive Agreement
4:32pm
8-K
EX-1.1
uhoei5x5xn fy
29 May 20
Entry into a Material Definitive Agreement
4:07pm
8-K
EX-99.1
n3i4fx
13 Jan 20
Results of Operations and Financial Condition
9:14am
8-K
EX-10.1
hqr uolxgq3qld
3 May 19
Entry into a Material Definitive Agreement
4:01pm
DEFA14A
nh99h8si2
26 Apr 19
Additional proxy soliciting materials
4:08pm